RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Budget impact of adding peginterferon beta-1A to the formulary for the treatment of relapsing forms of multiple sclerosis
Mauskopf, J., Graham, J., Fay-Azhar, M., & Kinter, E. (2015). Budget impact of adding peginterferon beta-1A to the formulary for the treatment of relapsing forms of multiple sclerosis. Value in Health, 18(3), A280-A281. https://doi.org/10.1016/j.jval.2015.03.1638
To estimate the budget impact of adding peginterferon beta-1a, a new interferon requiring injections only every two weeks for the treatment of relapsing forms of multiple sclerosis (MS), to a managed care formulary in the US.
